Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)

PURPOSE: Codrituzumab, a humanized antibody against glypican-3, is highly expressed in HCC. A phase I study evaluated the combination with sorafenib in HCC. PATIENTS AND METHODS: In a 3 + 3 design, codrituzumab was given intravenously in various doses with sorafenib 400 mg twice daily to patients wi...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Chemother Pharmacol
Main Authors: Abou-Alfa, Ghassan K., Yen, Chia-Jui, Hsu, Chih-Hung, O’Donoghue, Joseph, Beylergil, Volkan, Ruan, Shutian, Pandit-Taskar, Neeta, Gansukh, Bolorsukh, Lyashchenko, Serge K., Ma, Jennifer, Wan, Peter, Shao, Yu-Yun, Lin, Zhong-Zhe, Frenette, Catherine, O’Neil, Bert, Schwartz, Lawrence, Smith-Jones, Peter M., Ohtomo, Toshihiko, Tanaka, Takayoshi, Morikawa, Hideo, Maki, Yuko, Ohishi, Norihisa, Chen, Ya-Chi, Agajanov, Tamara, Boisserie, Frederic, Di Laurenzio, Laura, Lee, Ray, Larson, Steven M., Cheng, Ann-Lii, Carrasquilo, Jorge A.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5548107/
https://ncbi.nlm.nih.gov/pubmed/28120036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-017-3241-9
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki